Companies: 10,795·Total market cap: $144.5T
Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

VERANASDAQHealthcare● Active
$31.75
$-0.54(-1.67%)
Market Cap$2.3B
P/E Ratio
52W High$56.05
52W Low$19.066

Vera Therapeutics, Inc. (VERA) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

vera · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Vera Therapeutics, Inc. (VERA) measures how much investors pay for each dollar of the company's trailing earnings. VERA's current PE ratio of N/A is calculated by dividing its stock price of $31.75 by its TTM earnings per share of -$5.16.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-3.73
Based on 8 analysts
EPS (TTM)
-$5.16
TTM · diluted EPS
PEG Ratio
0.13
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-08

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Vera Therapeutics, Inc.
Vera Therapeutics, Inc.You
VERA
$2.3BN/A-$5.16
AbCellera Biologics Inc.
AbCellera Biologics Inc.
ABCL
$1.7BN/A-$0.49
Biohaven Ltd.
Biohaven Ltd.
BHVN
$1.2BN/A-$6.86
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
CLDX
$1.9BN/A-$3.89
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc.
HRMY
$1.9B13.56x$2.76
Immunome, Inc.
Immunome, Inc.
IMNM
$1.8BN/A-$2.43
Janux Therapeutics, Inc.
Janux Therapeutics, Inc.
JANX
$824MN/A-$1.83

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-4.66
2024-12-31
FY2024
$-2.75
2023-12-31
FY2023
$-2.25
2022-12-31
FY2022
$-3.35
2021-12-31
FY2021
$-2.43
2020-12-31
FY2020
$-14.40
2019-12-31
FY2019
$-3.46

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Vera Therapeutics, Inc. (VERA) measures how much investors pay for each dollar of the company's trailing earnings. VERA's current PE ratio of N/A is calculated by dividing its stock price of $31.75 by its TTM earnings per share of -$5.16.

PE Ratio = Stock Price ÷ EPS (TTM)
= $31.75 ÷ -$5.16 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

VERA pe ratio · 6 questions

VERA's current PE ratio is N/A as of 2026-06-08, based on a stock price of $31.75 and TTM EPS of -$5.16. Data sourced from Financial Modeling Prep via VERA's SEC 10-K and 10-Q filings.

VERA PE ratioWhat is VERA PE ratioCurrent PE ratio of VERAVERA PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Vera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08